• Advised a global biopharmaceutical company on its combination with a special purpose acquisition company, with the combined company valued at $2.25 billion*
• Advised a hormone optimisation company on its combination with with a special purpose acquisition company, with the combined company valued at $737 million*
• Advised a leading medical device company on its agreement to sell its cardiology business for $1.75 billion*
• Advised a clinical-stage global biotechnology company on its sale to an American multinational pharmaceutical and biotechnology corporation for up to $810 million*
• Advised a manufacturer of medical devices on its acquisition of a digital health company focused on sleep apnea diagnosis, for $538 million*
• Advised a specialty pharmaceutical company on its acquisition of a commercial stage biopharmaceutical group*
• Advised a global leader in digital consumer intelligence and social media listening on its sale for $450 million*
• Advised a global comprehensive communications platform on its acquisition of an advanced social and news media monitoring company*
• Advised the world’s premier social suite on its acquisition of a comprehensive influencer marketing platform*
• Advised one of the largest shareholders of a large online casino in connection with winning the auction for a British gambling company’s European assets for $2.76 billion*
• Advised a digital analytics platform on its acquisition of a digital analytics tool that monitors customer engagement actions and provides insights into user behavior*
• Advised a global marketing agency on its acquisitions of an industry-leading digital marketing agency*
• Advised a software company its $188 million acquisition of one of the leading contract analytics and artificial intelligence (AI) technology providers*
• Advised a leading New Space company on its acquisition of a satellite technology developer based in Virginia*
• Advised a web-based platform offering services to the production industry on its sale to a TPG Capital portfolio company*
• Advised a leading fully integrated biopharmaceutical solutions organisation on its acquisitions of a leading provider of clinical research home health services and a Latvian research company*
• Advised a clinical-stage biotech company on its reverse merger to create a public company focused on the development of innovative therapeutics for fibrosis-related diseases*
• Advised a biotech company on its acquisition of a biotech company that combines advanced microscopy with AI to help pharmaceutical companies to develop new drugs, for $60.6 million*
• Advised a global specialty oncology pharmaceutical company on its acquisition of a leading developer of off-the-shelf CAR-NKT cell immunotherapies, for $185 million*
• Advised a developer of fiber optics- and terahertz-based technologies, on its acquisition of a company specializing in fiber optic sensing from a multinational defence technology company*
• Advised a global leader in application modernization on its sale to a British healthcare and business software manufacturer*
• Advised an online marketplace company on its acquisition of a UK digital travel company*
• Advised a Norweigan private investment firm on the merger of a European parking collection company into a US leading provider of smart transportation solutions*
• Advised a Finnish multinational telecommunications corporation on its:
  • $17 billion combination with a telecommunications equipment company*
  • Joint venture with a Chinese investment and development company*
  • Acquisition of a Japanese security device manufacturer*
  • $1.2 billion acquisition of an American consumer electronics manufacturer’s wireless network infrastructure assets*
• Advised a medical device company on its sale of its advanced wound dressings manufacturing facility to global strategic outsource partner for healthcare & consumer companies*
• Advised a venture capital firm, on its acquisition of an English cloud service company by an American telecommunications company*
• Advised a Danish transport and logistics company on its $1.3 billion acquisition of a global supply chain management business*
• Advised a growth equity firm and other shareholders on the sale of an endpoint security software company*
• Advised a Luxembourg-based multinational steel manufacturing corporation on its $33.8 billion merger with an Indian steel producer*
• Advised an American multinational investment bank as financial adviser to a world leader in communications services on its acquisition of a British telecommunications company for $5.3 billion*
• Advised an American multinational investment bank as financial adviser to a Spanish multinational telecommunications company on its sale of a controlling stake in its Czech division*
• Advised an American dental equipment manufacturer on its $1.8 billion acquisition of a dental implant technology from an Anglo-Swedish multinational pharmaceutical and biotechnology company*
• Advised a chemicals company on its $22.2 billion acquisition of the largest licensor of polyethylene and polypropylene technologies*
• Advised a European multinational healthcare company on its acquisition of an American pharmaceutical company for $5.6 billion*
• Advised a global luggage company on its $1.7 billion sale to a Luxembourg-based private equity firm*
• Advised numerous leading global banks and financial service corporations as financial advisers on various high-profile transactions*

*Matter handled prior to joining McDermott

See less

As a member of the industry’s only crypto-exclusive team whose members spend 100% of their time on crypto-related matters, Nishi combines his regulatory knowledge with on the ground industry experience to provide actionable and practical counsel.

An active board member of the Association of Certified Anti-Money Laundering Specialists (ACAMS) New York Chapter, Nishi has also presented on crypto anti-money laundering and other compliance topics at several ACAMS events. He began his career as an investigative analyst in the Investigation Division of the New York County District Attorney’s Office.

See less

• Provided regulatory counsel to Anzens, Inc. on the issuance of the Cardano stablecoin USDA
• Provided regulatory counsel to BitcoinIRA, the world’s first provider of cryptocurrency investment retirement accounts
• Providing ongoing regulatory advice and legal support to one of the world’s largest centralized crypto exchanges
• Providing ongoing regulatory advice and legal support to a US and global cryptocurrency exchange with a related blockchain analytics platform, which is one of the most prominent in the world

See less

Matt is the Chicago lead of McDermott’s Litigation Practice Group and co-lead of the criminal investigations and prosecutions practice. He regularly represents executives, physicians, health systems, and companies in civil and criminal government investigations, including matters before and litigation against, DOJ, the US Securities & Exchange Commission (SEC), and the Office of Inspector General for the United States Department of Health and Human Services, among other agencies. Matt leads sensitive internal investigations and responds to government inquiries across a broad array of subject matters and areas of law, with a particular focus on matters involving accounting, antitrust, the False Claims Act, insider trading, securities fraud, healthcare fraud, trade fraud, bribery, and wire fraud.

Matt previously held numerous supervisory positions at the USAO, including criminal chief, chief of general crimes, and deputy chief of financial crimes. As criminal chief, he led approximately 125 assistant US attorneys in the Criminal Division, supervised the USAO’s most complex, high-profile investigations, and oversaw the implementation and development of the USAO’s policies.

During his tenure as a federal prosecutor, Matt was regarded as one of the top trial lawyers at the USAO. He led the successful 11-week trial against the former senior executives of Outcome Health for a $1 billion corporate, bank, and investor fraud scheme in a case that Crain’s Chicago Business called “one of the most high-profile and lengthy white-collar cases in Chicago history” and “a high-profile victory for the federal prosecutors in a complex and messy case that was largely circumstantial.” During another year, Matt tried eight cases, seven as first chair. He is also a seasoned appellate lawyer, having handled more than 15 appeals before the US Court of Appeals for the Seventh Circuit, with 10 oral arguments.

Matt has led and supervised dozens of trials and hundreds of investigations involving nearly every type of federal criminal offense, including securities fraud, healthcare fraud, insider trading, money laundering, Racketeer Influenced and Corrupt Organizations Act offenses, cybercrimes, bank fraud, mail and wire fraud, and terrorism. He worked closely with DOJ Criminal Division components, including the Fraud Section, and conducted numerous grand jury investigations that involved parallel securities fraud investigations by the SEC. Matt’s extensive experience and deep government ties are instrumental to advising clients facing government enforcement matters.

Before joining the USAO, Matt was an associate at McDermott and clerked for Judge Larry J. McKinney of the US District Court for the Southern District of Indiana and Judge William J. Bauer of the Seventh Circuit. In addition to his legal practice, he is guest faculty for trial advocacy at the University of Chicago Law School and has served in other faculty positions at law schools and the DOJ National Advocacy Center throughout his career.

See less

• Led the investigation, prosecution, and 11-week trial of the former CEO, President, and CFO of Outcome Health for a $1 billion fraud scheme, which included negotiation of a non-prosecution agreement with the company, work in parallel with the SEC during a two-year investigation that gathered more than 10 million documents, and presentation of four-hour rebuttal argument to jury after more than 20 hours of defense closing arguments, after which the presiding district court judge, in complimenting both the government attorneys and the defense attorneys, said, “in 45 years, I haven’t seen a performance like this, ever … the work the attorneys did in this case, at least in my judgment with the experience I’ve had, this is unparalleled”*
• Conducted internal investigation for global technology company with operations in over 150 countries
• Represented the former CFO of a government contractor in criminal and SEC cases related to alleged stock options backdating
• Represented national property and financial services company in Consumer Finance Protection Bureau investigation
• Represented a major food service retailer in multidistrict class action litigation related to alleged allergen content in food products
• Successfully tried a bank fraud case against a prominent real estate developer involving a $105 million line of credit*
• Successfully tried a healthcare fraud case against a healthcare business owner*
• Led the prosecution and successful trial against a Cook County judge on mortgage fraud charges*
• Led the securities fraud prosecution of former CEO and CFO of information technology software company*
• Successfully tried an investment company sales executive in $28 million investor fraud prosecution*
• Led the successful trial against pastor and wife who defrauded the state of Illinois childcare subsidy program*
• Investigated and prosecuted more than 40 individuals on public corruption, passport fraud, and identity theft charges in scheme involving bribes paid to Illinois Secretary of State employees*
• Investigated and prosecuted more than 40 individuals on violent crimes charges after long-term investigation of Traveling Vice Lords gang following murder of Chicago Police Department detective, and served as trial counsel on seven trials and dozens of hearings related to investigation*

*Matter handled prior to joining the firm.

See less

Katie also regularly counsels clients on insurance regulatory compliance and general corporate matters, serving as a trusted advisor on issues critical to their operations and growth. She brings practical, business-oriented insights to matters involving corporate governance, key commercial agreements, intellectual property, and employment law considerations.

Known for her collaborative approach and deep insurance industry knowledge, Katie takes pride in building long-term partnerships with clients and helping them achieve their strategic objectives.

Katie is a member of the firm’s Chicago Office Pro Bono Committee. She maintains an active pro bono practice, having represented nonprofit organizations in governance and employment matters, as well as asylum seekers and refugees fleeing persecution abroad.

See less

• Represented a private investment and direct lending firm in an investment in a reciprocal inter-insurance exchange, the proceeds of which will be contributed as regulatory capital.
• Represented Waypoint Underwriting Management, LLC, a specialty reinsurance platform, in its sale to Equinox Management Group, Inc., an affiliate of One80 Intermediaries Inc.
• Represented Bain Capital Insurance Fund and Emerald Bay Risk Solutions in the formation of a new property and casualty hybrid carrier platform for long-term managing general agent partnerships
• Represented Athene Holding Ltd. in its $1.24 billion initial public offering and multiple follow-on equity offerings*
• Represented Health Care Service Corporation in the issuance of $2.5 billion in senior unsecured notes*
• Represented Ohio National Life Insurance Company in a strategic transaction with Constellation Insurance Holdings involving Ohio National’s sponsored demutualization, providing for Constellation to fund cash payments or policy benefits in the amount of $500 million*
• Represented HUB International Limited and its affiliates in various acquisitions of insurance agencies through asset and stock acquisitions*

*Matter handled prior to joining McDermott Will & Schulte

See less

Known for his relentless work in pursuing the interests of his clients, Alexei’s approach to financings and other transactions is as strategic as it is innovative. As such, he often develops and drives the terms of deals in which he is involved.

Alexei’s experience includes advising on more than $60 billion in closed transactions for public, private equity- and venture-backed companies and investment funds. He also served as a senior executive with two prominent growth companies, one of which raised more than $60 million, the other upwards of $240 million.

Drawing on his experience representing companies that are first to market with disruptive products, services and technologies, Alexei tailors his advice to help clients achieve competitive advantages and navigate the many inherent regulatory risks that arise in the pursuit of new technologies and other products, services and solutions. He is well versed in traditional and emerging industries alike, including information technology; e-commerce; biotech; pharma and healthcare; food, beverage, and other consumer products; entertainment, media, and telecom; energy (including clean tech) and financial services.

Previously, Alexei served as an economic development commissioner for Arlington County, Virginia, during which time he also served as vice chairman of the commission. In this capacity, he focused on improving the regulatory climate for business and increasing the county’s economic competitiveness.

See less

• Represented Upright Citizens Brigade and its owners (including Amy Poehler) in UCB’s sale to an investment group, which was backed by Elysian Park Ventures*
• Represented Nielsen BuzzMetrics in various matters, including its acquisition of Intelliseek*
• Represented Halle Berry in various transactional matters*
• Represented A-list talent in the formation and financing of a consumer food business*
• Represented A-list talent in a joint venture in the consumer telcom sector*
• Represented a leading independent film studio in the sale of its film library*
• Represented Panasonic in various transactions, including the sale of the XUMO advertising-supported streaming service to Comcast*

Other Representative Transactions

• Represented Apostrophe, a teledermatology platform, in connection with its sale to Hims & Hers Health, Inc.*
• Represented Broadwing in its $1.4 billion merger with Level 3 Communications*
• Represented Citigroup in its $12.5 billion acquisition of Grupo Financiero Banamex-Accival (Banacci), Mexico’s largest financial services company*
• Represented ClassPass, a premier fitness membership, in each of its equity financings, including its $285 million Series E financing; its acquisitions of ClickyPass, fitmob, FitnessCollection, GuavaPass, and MuvPass; and its merger with Mindbody and the companion $500 million equity financing for the combined company*
• Represented Drummond Company in the sale of its Shoal Creek mining business to Peabody Energy*
• Represented Emerson Electric in the formation of its Louisville Ladder Group cross-border joint venture with Grupo IMSA*
• Represented Endesa (Spain) in its $1.5 billion acquisition of Enersis and its $2.1 billion acquisition of Endesa-Chile, two of Latin America’s largest power companies*
• Represented Glenmark Pharmaceuticals in its unique royalty agreement with Paul Capital Partners to finance the development of dermatological products for the US market*
• Represented Hain Celestial in its acquisition of ParmCrisps and Thinsters*
• Represented The Hershey Company in various M&A transactions and investments*
• Represented ImClone in its agreement with a leading pharmaceutical company for the development and commercialization of Erbitux® (its leading anti-cancer product), as well as with respect to the company’s related equity investment*
• Represented Kraft Foods in various dispositions*
• Represented Limited Brands in various matters, including the sale of Lane Bryant*
• Represented Polymedica in the sale of its women’s healthcare business*
• Represented Repsol in its $15 billion acquisition of YPF, Latin America’s largest petroleum company*
• Represented SineWave Ventures in the formation of its venture funds and in all of its investments*

*Matter handled prior to joining the firm.

See less

In addition, Julia represents clients in connection with governance, executive compensation, and other corporate and commercial matters. Her clients come from a wide range of industries, including healthcare, technology, education, financial services, entertainment, consumer goods, manufacturing and general industrials.

Passionate about promoting justice, diversity, equity and inclusion, Julia is a co-founder of Senior Women in Private Equity (SWIPE), a networking organization for senior female professionals at private equity, private credit and venture capital firms. SWIPE has over 3,500 members globally.

See less

• Represented Palladium Equity Partners in the sale of its portfolio company, Teasdale Food, Inc. (a leading producer and marketer of bean and hominy products in the United States) to Snow Phipps Group, LLC*
• Represented Great Hill Partners in connection with: (i) its acquisition of Quantum Holdings, a healthcare services company, from its stockholders including GE Ventures and Altaris Capital Partners, (ii) the sale of Network Merchants, LLC (NMI) to Francisco Partners and (iii) the sale of its portfolio company, DealerRater, to Cars.com, a TEGNA, Inc. company*
• Represented Bregal Sagemount in connection with: (i) the sale of its portfolio company, Kegs Logistics, an outsourced keg management provider) to Seaport Capital, (ii) the sale of Network Merchants, LLC (NMI) to Francisco Partners and (iii) the sale of its portfolio company, Tradeglobal, to Singapore Post Limited*
• Represented Behrman Capital in connection with: (i) the sale of its portfolio company, Selig Sealing Products to Henry Crown & Company and (ii) its acquisition of BECO Holding Company, the nation’s leading business-to-business wholesale distributor of first-response fire protection equipment and related parts, from Freeman Spogli & Co.*
• Represented Primus Capital Partners in connection with (i) its acquisition of Payspan, Inc., a healthcare technology company that provides payment automation services and (ii) its acquisition of Skill Survey, Inc., a provider of cloud-based solutions to help human capital management professionals to more effectively recruit, hire and manage employees*
• Represented Insight Venture Partners in connection with the sale of its portfolio company, OverDrive, Inc. to Rakuten, Inc. OverDrive is the leading eBook, audiobook and streaming video platform for libraries and schools*
• Represented TA Associates, in connection with (i) its sale of Viewpoint, Inc. to Bain Capital. Viewpoint is a leading provider of financial, accounting, compliance, operational, project and document management software for global construction companies and (ii) its acquisition of Paula’s Choice Holdings, Inc., a leading developer, distributor and marketer of skincare and cosmetics products*
• Represented New Enterprise Associates and affiliates in connection with its investments in: (i) Radiology Partners, the largest physician-led and physician-owned radiology practice in the U.S. and (ii) Bright Health, an insurtech company*
• Represented Gallus BioPharmaceuticals, LLC, a portfolio company of Ridgemont Equity Partners, in its sale to DPx Holdings, the parent company of Patheon and a portfolio company of JLL Partners. Gallus Biopharmaceuticals is a leading contract manufacturing company specializing in biologics*
• Represented Kilonova Capital in connection with its investment in Nanosys, Inc. Nanosys is an industry innovator and leading supplier of quantum dot and microLED technologies for advanced displays*
• Represented Fortress Investment Group in numerous investments in the healthcare, technology and media sectors*
• Represented to Utopus Insights, Inc. in its sale to Vestas Wind Systems A/S, Denmark. Utopus Insights is an energy analytics company in the renewable energy industry*
• Represented Norwood Medical in its sale to Heraeus Holding. Norwood Medical is a premier full-service provider of advanced outsourced medical manufacturing solutions*

*Matter handled prior to joining the firm.

See less

As a member of the senior leadership team at the FDA’s Center for Devices and Radiological Health, Paul advised agency officials on issues related to the regulatory scope of the FDA’s policies, programs, regulations, and legislation to the medical device industry. He also collaborated with the Office of Inspector General (OIG) and Government Accountability Office (GAO) on analyses, investigations and oversight of major national programs.

In addition to his government experience, Paul provides a commercially minded approach rooted in real-world experience as a business development executive at a national diagnostic biotechnology company. In that role, he worked with an international team on market entry and regulatory compliance issues to effectively launch and promote products in new market. Prior to joining McDermott Will & Schulte, Paul was a lawyer at several large national law firms.

See less

• Designed several phased regulatory strategies that position client offerings as consumer products that avoid or minimize FDA oversight to earn revenue while data is being generated to support the products’ future medical claims and/or functionalities*
• Advised several medical and consumer product manufacturers on whether product recalls or regulatory notifications were warranted based on product performance in the field. These decisions were not disputed by FDA during routine manufacturer inspections*
• Created a change of ownership plan for a portfolio of state licenses relating to the sale of a medical device company resulting in the uninterrupted sale of the acquired devices following the transaction*
• Guided a medical product company on the establishment and implementation of corrective actions that addressed FDA inspectional findings and were considered adequately responsive resulting in the closure of the inspection*
• Successfully petitioned FDA to take action against a medical product’s competitors that were marketing alleged “consumer products” with express and implied medical claims without the requisite FDA authorizations*
• Developed regulatory sections of the business overview and risk factors of an S-1 for an IPO of a prominent hybrid medical product and consumer product company IPO*
• Successfully represented a private equity firm in regulatory matters surrounding a gestational surrogacy platform purchase and bolt-on acquisitions*
• Provided streamlined regulatory diligence of several dozen publicly traded drug, biologic and medical device issuers on behalf of investment bank underwriters*

*Matter handled prior to joining the firm.

See less

Working with manufacturers and distributors of FDA-regulated products, Jamie brings deep experience on novel drugs, biologics, and cutting-edge products, from concept through post-market and marketing, helping clients reduce enforcement risk. He also assists on healthcare and life sciences transactions, providing FDA-related due diligence to maximize value and minimize roadblocks. 

When compliance or enforcement matters arise, Jamie takes a proactive, business-focused approach. He advises on the regulatory components of internal investigations, enforcement activity, and consumer protection litigation and has handled several responses to Office of Inspector General (OIG) and US Department of Justice (DOJ) subpoenas, as well as the defense and settlement of qui tam False Claims Act suits. 

A recognized thought leader in the health law and medical device spaces, Jamie is a regular speaker at industry conferences and has served on bio-innovation center and trade media editorial boards. Prior to joining McDermott Will & Schulte, he led the FDA, healthcare, and consumer products compliance practice at a large international law firm.

See less

• Advised a publicly traded healthcare products company in a transaction valued at up to $850 million, providing FDA and life sciences regulatory counsel in connection with the acquisition of a surgical products business.  

• Advised a global medical device manufacturer and private equity sponsor in the acquisition and post-closing integration of an orthopedic products company, including FDA, HIPAA, healthcare compliance, and regulatory diligence matters. 

• Advised private equity sponsors in acquisitions of clinical research organizations, clinical trial sites, medical device companies, healthcare services providers, and other FDA-regulated businesses, including transactions valued at more than $58 million, providing regulatory diligence and transaction risk assessments. 

See less

Michael has experience handling a variety of complex tax issues, including partnership audit procedures under the Tax Equity and Fiscal Responsibility Act of 1982 (TEFRA) and the Bipartisan Budget Act of 2015 (BBA), international tax and Report of Foreign Bank and Financial Accounts (FBAR) compliance, reportable transactions, transfer pricing, debt equity classifications, foreign tax credits and excise tax on reinsurers. He also advises on questions relating to the attorney-client and work product privileges arising in tax matters.

After law school, Michael served as a term law clerk for the Honorable Karen L. Hayes of the US District Court for the Western District of Louisiana. He also served as a judicial intern for the Honorable Dolores K. Sloviter of the US Court of Appeals for the Third Circuit during law school. And, while earning his LLM in Tax from NYU, he served as a legal extern for the Internal Revenue Service’s (IRS) Office of Chief Counsel and Large Business and International Division in New York.

Michael has contributed to several publications, including co-authoring articles in the Journal of Tax Practice & Procedure addressing potential abuse of CARES Act tax relief provisions, the BBA centralized partnership audit regulations, and the repeal of the TEFRA audit regime. He has also co-authored an article examining the United States’ role as a potential tax haven, published in The Champion.

See less

• Advised a Fortune 100 multinational corporation in restructuring its global tax department to optimize compliance with domestic and global reporting requirements and maintain confidentiality for sensitive, privileged materials*
• Advised a multinational pharmaceutical company regarding its captive insurance program*
• Successfully represented taxpayers before the IRS relating to the examination of Employee Retention Credits*
• Obtained full concession from the IRS in a US Tax Court matter affirming a taxpayer’s position that $50 million in proceeds from litigation funding was properly characterized as long-term capital gain*
• Successfully negotiated the resolution of a New York sales tax examination on behalf of a multinational company, its subsidiary and its executives as purported responsible persons*
• Obtained favorable resolution for a taxpayer regarding a criminal tax investigation into New York City’s unincorporated business tax*
• Successfully quashed a series of summonses served on US financial institutions pursuant to the United States-Russia tax treaty and at the request of the Russian Federation*
• Was part of a trial counsel team in a Tax Court case involving a large multinational hedge fund advisory firm that was to determine whether the fund was “engaged in a US trade or business” and was effectively generating connected income as result of its investment activities and whether the fund was subject to withholding under IRC Section 1446*
• Represented a large estate in a complex Tax Court case involving the valuation of an estate comprised of original works of art and the calculation of the appropriate blockage discount*
• Represented employers in worker classification issues and for participation in the IRS Voluntary Classification Settlement Program*

*Matter handled prior to joining the firm.

See less